DE69724619T2 - Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können - Google Patents
Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können Download PDFInfo
- Publication number
- DE69724619T2 DE69724619T2 DE69724619T DE69724619T DE69724619T2 DE 69724619 T2 DE69724619 T2 DE 69724619T2 DE 69724619 T DE69724619 T DE 69724619T DE 69724619 T DE69724619 T DE 69724619T DE 69724619 T2 DE69724619 T2 DE 69724619T2
- Authority
- DE
- Germany
- Prior art keywords
- prp
- chaperone
- protein
- prion protein
- gst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000029797 Prion Human genes 0.000 title claims abstract description 102
- 108091000054 Prion Proteins 0.000 title claims abstract description 102
- 108010006519 Molecular Chaperones Proteins 0.000 title claims abstract description 73
- 108010029485 Protein Isoforms Proteins 0.000 title claims description 20
- 102000001708 Protein Isoforms Human genes 0.000 title claims description 20
- 102000005431 Molecular Chaperones Human genes 0.000 title abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 230000027455 binding Effects 0.000 claims abstract description 24
- 208000024777 Prion disease Diseases 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 208000010544 human prion disease Diseases 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 101710138751 Major prion protein Proteins 0.000 claims description 129
- 102100025818 Major prion protein Human genes 0.000 claims description 129
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 84
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 33
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 26
- 229920002684 Sepharose Polymers 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 208000008864 scrapie Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 7
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 102000005720 Glutathione transferase Human genes 0.000 claims description 4
- 108010070675 Glutathione transferase Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 102000000584 Calmodulin Human genes 0.000 claims description 3
- 108010041952 Calmodulin Proteins 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 102100031673 Corneodesmosin Human genes 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 241000772415 Neovison vison Species 0.000 claims description 2
- 229940096437 Protein S Drugs 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 206010023497 kuru Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000006061 fatal familial insomnia Diseases 0.000 claims 2
- 238000002955 isolation Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 28
- 150000001413 amino acids Chemical group 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 239000000523 sample Substances 0.000 description 13
- 239000011324 bead Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000699673 Mesocricetus auratus Species 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 238000010276 construction Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012723 sample buffer Substances 0.000 description 5
- 238000010396 two-hybrid screening Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108091028026 C-DNA Proteins 0.000 description 3
- 102100037676 CCAAT/enhancer-binding protein zeta Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000880588 Homo sapiens CCAAT/enhancer-binding protein zeta Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 101710173438 Late L2 mu core protein Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 2
- GAKUNXBDVGLOFS-DUZKARGPSA-N (1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC GAKUNXBDVGLOFS-DUZKARGPSA-N 0.000 description 1
- JDXQWYKOKYUQDN-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione Chemical compound OC1CC(=O)NC1=O JDXQWYKOKYUQDN-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100166957 Anabaena sp. (strain L31) groEL2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 208000010711 Cattle disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- -1 Dynabeads Polymers 0.000 description 1
- 108700036061 EC 3.4.21.88 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101150007280 LEU2 gene Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710205482 Nuclear factor 1 A-type Proteins 0.000 description 1
- 102100022165 Nuclear factor 1 B-type Human genes 0.000 description 1
- 101710170464 Nuclear factor 1 B-type Proteins 0.000 description 1
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 description 1
- 101710113455 Nuclear factor 1 C-type Proteins 0.000 description 1
- 101710140810 Nuclear factor 1 X-type Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101100439396 Synechococcus sp. (strain ATCC 27144 / PCC 6301 / SAUG 1402/1) groEL1 gene Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 102000028861 calmodulin binding Human genes 0.000 description 1
- 108091000084 calmodulin binding Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 101150077981 groEL gene Proteins 0.000 description 1
- 101150006844 groES gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000046432 human HSPD1 Human genes 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000019143 inherited prion disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010056929 lyticase Proteins 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000007399 subcellular translocation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96107677 | 1996-05-14 | ||
| EP96107677 | 1996-05-14 | ||
| PCT/EP1997/002444 WO1997043649A1 (en) | 1996-05-14 | 1997-05-13 | CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69724619D1 DE69724619D1 (de) | 2003-10-09 |
| DE69724619T2 true DE69724619T2 (de) | 2004-07-01 |
Family
ID=8222782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69724619T Expired - Fee Related DE69724619T2 (de) | 1996-05-14 | 1997-05-13 | Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6451541B1 (https=) |
| EP (1) | EP0914614B1 (https=) |
| JP (1) | JP3745380B2 (https=) |
| AT (1) | ATE249046T1 (https=) |
| DE (1) | DE69724619T2 (https=) |
| WO (1) | WO1997043649A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1186662A3 (en) * | 1996-05-29 | 2003-01-15 | McGILL UNIVERSITY | Prion binding proteins and uses thereof |
| US6719988B2 (en) | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Antiseptic compositions for inactivating prions |
| US6720355B2 (en) | 1997-02-21 | 2004-04-13 | The Regents Of The University Of California | Sodium dodecyl sulfate compositions for inactivating prions |
| US6620629B1 (en) | 1997-02-21 | 2003-09-16 | The Regents Of The University Of California | Method for detecting prions |
| US5891641A (en) * | 1997-02-21 | 1999-04-06 | The Regents Of The University Of California | Assay for disease related conformation of a protein |
| US6617119B2 (en) | 1997-02-21 | 2003-09-09 | The Regents Of The University Of California | Assay for specific strains of multiple disease related conformations of a protein |
| AU764888B2 (en) * | 1997-02-21 | 2003-09-04 | Regents Of The University Of California, The | Assay for disease related conformation of a protein |
| US6221614B1 (en) * | 1997-02-21 | 2001-04-24 | The Regents Of The University Of California | Removal of prions from blood, plasma and other liquids |
| US5977324A (en) * | 1998-02-20 | 1999-11-02 | The Regents Of The University Of California | Process for concentrating protein with disease-related conformation |
| US6214565B1 (en) | 1998-10-09 | 2001-04-10 | The Regents Of The University Of California | Assay for disease related conformation of a protein and isolating same |
| US7041807B1 (en) | 1999-06-23 | 2006-05-09 | Caprion Pharmaceuticals, Inc. | Antibodies to a YYX epitope of a mammalian prion protein |
| AU5241100A (en) * | 1999-09-28 | 2001-04-30 | Universitat Zurich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| WO2001023894A1 (de) * | 1999-09-28 | 2001-04-05 | Evotec Oai Ag | Quantitative analyse und typisierung subzellulärer partikel |
| EP1395833B1 (en) | 2001-05-31 | 2013-02-27 | Adlyfe, Inc. | Misfolded protein sensor method |
| US20050026165A1 (en) | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| EP1414846A2 (en) * | 2001-08-10 | 2004-05-06 | Medical Research Council | Molecule |
| NZ536054A (en) * | 2002-04-09 | 2009-10-30 | Scripps Research Inst | Motif-grafted hybrid polypeptides and uses thereof |
| US20040072236A1 (en) * | 2002-09-27 | 2004-04-15 | Neil Cashman | PrPSc -interacting molecules and uses thereof |
| DK1573323T3 (da) * | 2002-12-03 | 2012-01-23 | Pathogen Removal & Diagnostic Technologies Inc | Prion-proteinligander samt fremgangsmåder til anvendelse deraf |
| WO2004090102A2 (en) | 2003-04-04 | 2004-10-21 | American Red Cross | Prion protein binding materials and methods of use |
| MX2007008497A (es) * | 2005-01-13 | 2007-09-14 | Novartis Vaccines & Diagnostic | Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion. |
| EP1853915B1 (en) * | 2005-02-15 | 2011-10-12 | Adlyfe, Inc. | Method for detecting misfolded proteins and prions |
| US7790364B2 (en) * | 2006-01-27 | 2010-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for high throughput screening of pharmacological chaperones |
| WO2008013859A2 (en) * | 2006-07-28 | 2008-01-31 | Adlyfe, Inc. | Peptide probes for diagnostics and therapeutics |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| WO1993023432A1 (en) * | 1992-05-15 | 1993-11-25 | New York University | Soluble prion polypeptides, and methods for detecting and purifying thereof |
| US5565186A (en) * | 1994-05-13 | 1996-10-15 | The Regents Of The University Of California | Method of detecting prions in a sample and transgenic animal used for same |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| MX9704738A (es) * | 1994-12-21 | 1997-10-31 | Yenda Res And Dev Co Ltd | Analogos de peptido p277 y composiciones farmaceuticas que los contienen, metodo de diagnostico de diabetes mellitus dependiente de la insulina y uso de los mismos. |
| IL114407A0 (en) * | 1995-06-30 | 1995-10-31 | Yeda Res & Dev | Novel peptides and pharmaceutical compositions comprising them |
-
1997
- 1997-05-13 WO PCT/EP1997/002444 patent/WO1997043649A1/en not_active Ceased
- 1997-05-13 JP JP54052297A patent/JP3745380B2/ja not_active Expired - Fee Related
- 1997-05-13 EP EP97923067A patent/EP0914614B1/en not_active Expired - Lifetime
- 1997-05-13 US US09/180,652 patent/US6451541B1/en not_active Expired - Fee Related
- 1997-05-13 AT AT97923067T patent/ATE249046T1/de not_active IP Right Cessation
- 1997-05-13 DE DE69724619T patent/DE69724619T2/de not_active Expired - Fee Related
-
2002
- 2002-03-27 US US10/106,825 patent/US20050227287A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0914614A1 (en) | 1999-05-12 |
| WO1997043649A1 (en) | 1997-11-20 |
| EP0914614B1 (en) | 2003-09-03 |
| JP3745380B2 (ja) | 2006-02-15 |
| US6451541B1 (en) | 2002-09-17 |
| JP2000516572A (ja) | 2000-12-12 |
| US20050227287A1 (en) | 2005-10-13 |
| DE69724619D1 (de) | 2003-10-09 |
| ATE249046T1 (de) | 2003-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69724619T2 (de) | Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können | |
| Edenhofer et al. | Prion protein PrPc interacts with molecular chaperones of the Hsp60 family | |
| JP4790966B2 (ja) | 構造疾患の検出方法、構造疾患マーカーのアッセイ、診断キット、構造変化調節化合物の同定方法、プリオンタンパク質の病原性形態の検出方法、及びβ−アミロイドタンパク質の病原性形態の検出方法 | |
| Walter et al. | Copper binding extrinsic to the octarepeat region in the prion protein | |
| EP2172486B1 (en) | Monoclonal antibody against a prion protein and its use for the detection of prions | |
| Melino et al. | Zn2+ ions selectively induce antimicrobial salivary peptide histatin-5 to fuse negatively charged vesicles. Identification and characterization of a zinc-binding motif present in the functional domain | |
| Hope et al. | Cytotoxicity of prion protein peptide (PrP106–126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, Aβ25–35 | |
| Krampert et al. | Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP) | |
| US5585239A (en) | Herpes simplex virus drug screen | |
| DE69909442T2 (de) | Assay für spezifische stämme von mit mehreren krankheiten zusammenhängenden proteinkonformationen | |
| Härtig et al. | Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice | |
| Buschmann et al. | Cellular prion proteins of mammalian species display an intrinsic partial proteinase K resistance | |
| Chao et al. | Use of a two-hybrid system to investigate molecular interactions of GAP-43 | |
| US6248532B1 (en) | Creba isoform | |
| US6020537A (en) | Prion protein standard and method of making same | |
| US7070940B2 (en) | Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein | |
| WO2002040512A2 (de) | Humanes beta-defensin-3 | |
| Tatzelt et al. | Abnormalities in stress proteins in prion diseases | |
| DE102005060920A1 (de) | Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung | |
| US5834593A (en) | Soluble form of PrPSC which is insoluble in native form | |
| Edenhofer et al. | Chemistry and molecular biology of transmissible spongiform encephalopathies | |
| KR20010030862A (ko) | 프리세닐린과 상호작용할 수 있는 단백질을 암호화하는 핵산 | |
| DE102004043782A1 (de) | Polypeptide und Verfahren zur spezifischen Bindung von Prionen | |
| JP2006515269A (ja) | 病原性／感染性タンパク質などのタンパク質においてコンホメーション転移を誘発させる方法 | |
| US20050266412A1 (en) | Method of amplifying infectious protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8339 | Ceased/non-payment of the annual fee |